FibroBiologics meets NASDAQ listing requirements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
FibroBiologics Compliant with All Nasdaq Listing Requirements
April 20, 2026 4:01 PM EDTHOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (FibroBiologics), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that The Nasdaq Stock Market LLC (Nasdaq) has confirmed that the Company has demonstrated compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $2.5 million stockholders equity requirement and the $1.00 bid price requirement.
The Company has now successfully resolved its Nasdaq compliance issues but will remain... More
